Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CFO Scott Burrows sold 7,500 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $87.74, for a total value of $658,050.00. Following the transaction, the chief financial officer directly owned 97,994 shares of the company’s stock, valued at $8,597,993.56. This represents a 7.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Spyre Therapeutics Stock Down 2.5%
Shares of NASDAQ:SYRE traded down $2.26 during midday trading on Thursday, reaching $86.63. The company’s stock had a trading volume of 973,914 shares, compared to its average volume of 1,804,648. The firm has a 50 day moving average of $77.77 and a 200-day moving average of $53.55. The firm has a market capitalization of $7.62 billion, a P/E ratio of -41.65 and a beta of 3.02. Spyre Therapeutics, Inc. has a 12-month low of $14.51 and a 12-month high of $102.06.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.08). On average, research analysts predict that Spyre Therapeutics, Inc. will post -2.86 EPS for the current year.
Institutional Investors Weigh In On Spyre Therapeutics
Analyst Upgrades and Downgrades
SYRE has been the topic of several recent research reports. JonesTrading upped their price target on Spyre Therapeutics from $64.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, April 17th. Wells Fargo & Company lifted their price objective on Spyre Therapeutics from $50.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. Citigroup increased their target price on Spyre Therapeutics from $64.00 to $97.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Jefferies Financial Group raised their price target on Spyre Therapeutics from $47.00 to $85.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, Leerink Partners lifted their price target on Spyre Therapeutics from $49.00 to $106.00 and gave the stock an “outperform” rating in a research report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Spyre Therapeutics has an average rating of “Buy” and a consensus price target of $95.83.
View Our Latest Stock Report on SYRE
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
See Also
- Five stocks we like better than Spyre Therapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
